All 33 ovarian serous tumors were assessed for mutations in KRAS, BRAF, PIK3CA, and ERBB2. Interestingly, all LGSC, SBT, and SCA cases showed wild-type KRAS variant (Table 1, Table 2 and Table 3). Here, ERBB2 is linked to ovarian serous tumor.